Jefferies Financial Group Upgrades UCB (OTCMKTS:UCBJY) to Hold

UCB (OTCMKTS:UCBJY) was upgraded by stock analysts at Jefferies Financial Group from a “moderate sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

UCBJY has been the subject of a number of other research reports. Zacks Research raised shares of UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

UCB Price Performance

UCBJY stock opened at $127.41 on Monday. UCB has a 52 week low of $106.09 and a 52 week high of $168.76. The company’s 50-day simple moving average is $143.25 and its 200 day simple moving average is $147.27. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.